These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Revisions to the requirements applicable to blood, blood components, and source plasma. Final rule. Food and Drug Administration, HHS Fed Regist; 2001 Aug; 66(151):40886-90. PubMed ID: 11732557 [TBL] [Abstract][Full Text] [Related]
6. Letter on Bacterial contamination in platelet concentrates. Harm SK; Delaney M; Aubuchon JP; Triulzi DJ; Yazer MH Vox Sang; 2014 Oct; 107(3):312. PubMed ID: 25040131 [No Abstract] [Full Text] [Related]
7. Proceedings of a consensus conference: Risk-Based Decision Making for Blood Safety. Leach Bennett J; Blajchman MA; Delage G; Fearon M; Devine D Transfus Med Rev; 2011 Oct; 25(4):267-92. PubMed ID: 21763103 [TBL] [Abstract][Full Text] [Related]
8. Trans people and blood donation. Goldman M; Butler-Foster T; Lapierre D; O'Brien SF; Devor A Transfusion; 2020 May; 60(5):1084-1092. PubMed ID: 32343438 [No Abstract] [Full Text] [Related]
9. Repeat voluntary non-remunerated blood donor is the best quality indicator for blood safety. Nair SC; Mammen JJ Indian J Med Res; 2015 Jun; 141(6):749-52. PubMed ID: 26205016 [No Abstract] [Full Text] [Related]
11. AIDS and the blood supply: an analysis of law, regulation, and public policy. Salbu SR Wash Univ Law Q; 1996; 74(4):913-80. PubMed ID: 16273697 [No Abstract] [Full Text] [Related]
12. Transfusion-related acute lung injury (TRALI): A Canadian blood services research and development symposium. Saidenberg E; Petraszko T; Semple E; Branch DR Transfus Med Rev; 2010 Oct; 24(4):305-24. PubMed ID: 20851333 [TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of predonation screening for transfusion transmissible infections using rapid test kits in a hospital-based blood transfusion centre. Dosunmu AO; Akinbami AA; Ismail AK; Olaiya MA; Uche EI; Aile IK Niger Postgrad Med J; 2017; 24(3):162-167. PubMed ID: 29082905 [TBL] [Abstract][Full Text] [Related]
14. Safety improving by complementary serological and molecular testing combined with pathogen reduction of the donated blood in window period. Balint B; Vucetic D; Todorovic-Balint M; Borovcanin N; Jovanovic-Cupic S; Mandusic V Transfus Apher Sci; 2013 Aug; 49(1):103-4. PubMed ID: 23820432 [No Abstract] [Full Text] [Related]
15. [Seventeen years of haemovigilance in France: assessment and outlook]. Carlier M; Vo Mai MP; Fauveau L; Ounnoughene N; Sandid I; Renaudier P Transfus Clin Biol; 2011 Apr; 18(2):140-50. PubMed ID: 21474356 [TBL] [Abstract][Full Text] [Related]
17. Revisiting Factor VIII cases: is it time for an agency adjudication system? Su YC Food Drug Law J; 2008; 63(4):943-61. PubMed ID: 19601390 [No Abstract] [Full Text] [Related]
18. Advancing risk assessment for emerging infectious diseases for blood and blood products: proceedings of a public workshop. Gallagher LM; Ganz PR; Yang H; Kessler DA; O'Brien SF; Custer BS; Busch MP; Dodd RY; Stramer SL; Walderhaug MO; Forshee RA; Williams AE; Epstein JS; Anderson SA Transfusion; 2013 Feb; 53(2):455-63. PubMed ID: 22845334 [No Abstract] [Full Text] [Related]
19. Current good manufacturing practices for transfusion medicine. Sazama K Transfus Med Rev; 1996 Oct; 10(4):286-95. PubMed ID: 8899957 [TBL] [Abstract][Full Text] [Related]
20. Develop a useful donor-screening process. Harty-Golder B MLO Med Lab Obs; 2003 Oct; 35(10):34. PubMed ID: 14571850 [No Abstract] [Full Text] [Related] [Next] [New Search]